Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study

INTRODUCTION: iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, is one option for treatment intensification in individuals with type 2 diabetes (T2D) who are unable to achieve targeted glycaemic control with th...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyoshi, Hideaki, Matsuhisa, Munehide, Yabe, Daisuke, Takahashi, Yoko, Morimoto, Yukiko, Terauchi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064399/
https://www.ncbi.nlm.nih.gov/pubmed/36809494
http://dx.doi.org/10.1007/s13300-023-01373-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064399/
https://www.ncbi.nlm.nih.gov/pubmed/36809494
http://dx.doi.org/10.1007/s13300-023-01373-w

Ejemplares similares